-+ 0.00%
-+ 0.00%
-+ 0.00%

AlphaValue/Baader Europe Lifts Sanofi Price Target Amid Continued Dupixent Strength

MT Newswires·11/06/2026 07:32:30
Listen to the news
07:32 AM EST, 11/06/2026 (MT Newswires) -- AlphaValue/Baader Europe increased its price target for Sanofi (SAN.PA) to 109 euros from 104 euros, largely attributing the French pharmaceutical group's growth in recent years to its immunology drug Dupixent. "An impressive beat in Q3 26, again led by Dupixent, has prompted an upgrade to our earnings estimates and target price. Nonetheless, for Sanofi's shares to enjoy a sustained re-rating, the new CEO has to provide concrete answers to investors' apprehensions around the firm's life after Dupixent," analysts wrote in a Friday note. "We see bold and decisive acquisitive actions as the need of the hour, but it must be balanced against the risk of overpaying." The research firm has an add rating on the stock.